Farxiga (dapagliflozin) is an SGLT2 inhibitor commonly added to metformin in adults with type 2 diabetes whose A1C remains above target on metformin alone. The two drugs have complementary mechanisms — metformin suppresses hepatic glucose output and improves insulin sensitivity; Farxiga causes the kidneys to excrete excess glucose in urine. Combined therapy lowers A1C by an additional 0.5 to 0.8 percentage points and produces modest weight loss and blood pressure reduction. Farxiga also has separate FDA indications for heart failure and chronic kidney disease, which makes it a useful add-on even when glucose control is acceptable.
Why These Two Drugs Are Often Combined
Metformin is the foundation of type 2 diabetes care. When a patient does not reach A1C target on metformin, an add-on is needed. Farxiga is one of several second-line options; it is preferred over some alternatives when the patient also has:
- Heart failure (reduced or preserved ejection fraction)
- Chronic kidney disease with albuminuria
- Atherosclerotic cardiovascular disease
- A goal of modest weight loss and blood pressure reduction
The ADA 2024 Standards of Care list SGLT2 inhibitors (including Farxiga) and GLP-1 receptor agonists as preferred add-ons after metformin in patients with these conditions.
How the Two Drugs Work Together
| Drug | Main Mechanism | A1C Reduction (Monotherapy) | Weight Effect | Hypoglycemia Risk |
|---|---|---|---|---|
| Metformin | Reduces hepatic glucose production; improves insulin sensitivity | -1.0 to -1.5% | -1 to -2 kg | Low |
| Farxiga (dapagliflozin) | Inhibits SGLT2 in the kidney; glucose excreted in urine | -0.5 to -1.0% | -2 to -3 kg | Low |
| Combination | Both mechanisms additive | -1.5 to -2.0% total | -3 to -5 kg | Low (higher only with insulin or sulfonylureas) |
Clinical Evidence
The DECLARE-TIMI 58 trial enrolled over 17,000 adults with type 2 diabetes, most on metformin. Compared with placebo, Farxiga reduced the composite of cardiovascular death or hospitalization for heart failure by 17 percent and reduced progression of kidney disease by 24 percent. The DAPA-HF and DELIVER trials extended the heart failure benefit to patients without diabetes, and DAPA-CKD confirmed the kidney benefit independent of diabetes status. These findings are part of why Farxiga is prescribed beyond pure glucose control.
Dosing
- Farxiga: 5 mg once daily, with or without food; may increase to 10 mg daily after 2 weeks if needed and tolerated. 10 mg is the standard dose for most indications.
- Metformin immediate release: 500 mg twice daily with meals initially, titrating up to 1000 mg twice daily (max 2,000 to 2,550 mg per day)
- Metformin extended release: 500 to 2,000 mg once daily with the evening meal
- Xigduo XR: combination tablet containing dapagliflozin plus metformin extended release (various strengths: 5/500, 5/1000, 10/500, 10/1000)
Who Benefits Most From Combination Therapy
- Adults with type 2 diabetes and A1C above target on metformin alone
- Patients with established atherosclerotic cardiovascular disease
- Patients with heart failure (with or without diabetes)
- Patients with chronic kidney disease and albuminuria
- Patients who would benefit from modest weight loss and blood pressure reduction
When Farxiga Is Not the Right Add-On
- eGFR persistently below 25 mL/min/1.73m² (check current label, which has evolved)
- Type 1 diabetes (increased risk of DKA)
- Recurrent urinary tract or genital yeast infections
- History of Fournier’s gangrene or prior severe genital infection
- Significant hypotension or volume depletion
- Active pancreatitis
Common Side Effects
| Side Effect | Approx Incidence | Notes |
|---|---|---|
| Genital yeast infection | 4 to 6% (women > men) | Responds to topical antifungal; preventable with hygiene |
| Urinary tract infection | 3 to 5% | More common in women |
| Increased urination | Common | Usually settles after first few weeks |
| Dehydration / volume depletion | 1 to 3% | More common in older adults, those on diuretics |
| Hypoglycemia | Low on metformin + Farxiga alone; higher with insulin/sulfonylureas | Reduce insulin or sulfonylurea dose when starting |
Serious but Uncommon Risks
- Euglycemic DKA — ketoacidosis at normal glucose; risk is higher in type 1 diabetes and during prolonged fasting, surgery, or illness. Stop Farxiga before elective surgery per package insert.
- Fournier’s gangrene — very rare necrotizing fasciitis of the perineum; any severe genital-area infection needs urgent evaluation.
- Lower-limb amputation — small signal seen with canagliflozin (CANVAS trial); dapagliflozin has shown lower risk, but caution in patients with prior amputation or severe peripheral vascular disease.
- Bone fractures — small signal with some SGLT2 inhibitors; consider monitoring in high-risk patients.
Monitoring on Combination Therapy
- A1C every 3 to 6 months
- Basic metabolic panel (including eGFR) every 3 to 6 months, more often if kidney function is marginal
- Blood pressure at each visit
- Vitamin B12 annually (metformin can reduce B12 absorption over long-term use)
- Urinalysis or urine albumin-to-creatinine ratio yearly for diabetic kidney disease screening
Cost Considerations
- Metformin generics: very inexpensive ($4 to $10 per month)
- Farxiga: no US generic; list price around $500+ per month, though commercial insurance and manufacturer savings cards typically reduce out-of-pocket cost substantially
- Xigduo XR (combination): similar cost to Farxiga alone
- Medicare Part D negotiated pricing under the Inflation Reduction Act may lower cost in future years if dapagliflozin is added to the negotiated list
Related Reading
For broader context on SGLT2 inhibitors and diabetes care, see our treatment hub, our page on whether Jardiance has a generic, and our overview of A1C levels.
The Bottom Line
Farxiga and metformin together are a well-established second-line combination for type 2 diabetes. The two drugs have complementary mechanisms, add about 0.5 to 0.8 percentage points of A1C reduction beyond metformin alone, produce modest weight loss, and bring meaningful cardiovascular and kidney benefits. The main side-effect concerns are genital yeast infections and rare DKA. When kidney function, heart failure, or cardiovascular disease are part of the picture, this combination often does more than glucose control alone and earns its place in the regimen.
